Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8431806 | CELATOR PHARMS | Liposomal formulations of anthracycline agents and cytidine analogs |
Apr, 2025
(11 months from now) | |
US8518437 | CELATOR PHARMS | Lipid carrier compositions with enhanced blood stability |
Jun, 2026
(2 years from now) | |
US7850990 | CELATOR PHARMS | Compositions for delivery of drug combinations |
Jan, 2027
(2 years from now) | |
US9271931 | CELATOR PHARMS | Compositions for delivery of drug combinations |
Jan, 2027
(2 years from now) | |
US8022279 | CELATOR PHARMS | Liposomal formulations of anthracycline agents and cytidine analogs |
Sep, 2027
(3 years from now) | |
US8092828 | CELATOR PHARMS | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
Apr, 2029
(4 years from now) | |
US10028912 | CELATOR PHARMS | Method of lyophilizing liposomes |
Oct, 2032
(8 years from now) | |
US10835492 | CELATOR PHARMS | Method of lyophilizing liposomes |
Oct, 2032
(8 years from now) | |
US10166184 | CELATOR PHARMS | Method of lyophilizing liposomes |
Oct, 2032
(8 years from now) |
Vyxeos is owned by Celator Pharms.
Vyxeos contains Cytarabine; Daunorubicin.
Vyxeos has a total of 9 drug patents out of which 0 drug patents have expired.
Vyxeos was authorised for market use on 03 August, 2017.
Vyxeos is available in powder;intravenous dosage forms.
Vyxeos can be used as method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older, method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older, for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older.
The generics of Vyxeos are possible to be released after 15 October, 2032.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-350) | Mar 30, 2028 |
New Patient Population(NPP) | Mar 30, 2024 |
Orphan Drug Exclusivity(ODE-287) | Aug 03, 2024 |
New Product(NP) | Aug 03, 2020 |
Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient
Market Authorisation Date: 03 August, 2017
Treatment: For the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in adults and pediatric patients 1 year and older; Method of re...
Dosage: POWDER;INTRAVENOUS